How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis

CMAJ. Canadian Medical Association Journal

Volumn 165, Issue 11, 2001, Pages 1475-1488

  Schachter, Howard M ^a   Pham, Ba' ^a   King, Jim ^a   Langford, Stephanie ^a   Moher, David ^a  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; PLACEBO;

ADOLESCENT; AGE; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DATA ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERACTIVITY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 0035687397     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents
2. Treatment of attention-deficit/hyperactivity disorder
3. ADHD: A new practice guideline from the American Academy of Pediatrics
4. What the multimodal treatment study of children with attention-deficit/hyperactivity disorder did and did not say about the use of methylphenidate for attention deficits
5. Whose order is being disordered by ADHD?
6. Trends in the prescribing of psychotropic medications to preschoolers
7. Practice parameters for the assessment and treatment of children, adolescents and adults with attention-deficit hyperactivity disorder
8. Attention deficit hyperactivity disorder: Advances in cognitive, neurobiological, and genetic research
9. Attention deficit disorder: Diagnosis and role of Ritalin in management
10. Some reasons for concern about attention deficit hyperactivity disorder
11. Treatment
12. Personal paper: ADHD is underdiagnosed and undertreated in Britain
13. Attention-deficit hyperactivity and hyperkinetic disorder
14. Stimulants
15. Attention-deficit hyperactivity disorder: The stimulants
16. Stimulant medications
17. National Institutes of Health Consensus Development Conference statement: Diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD)
18. Stimulant medications for the treatment of ADHD: Efficacy and limitations
19. Attention deficit hyperactivity disorder
20. Attention deficit disorder: A review of the past 10 years
21. Conners' Rating Scales - Revised
22. American Academy of Pediatrics' clinical practice guideline: Diagnosis and evaluation of the child with attention-deficit /hyperactivity disorder
23. Clinical practice guideline. Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics
24. The efficacy of stimulant drug treatment for hyperactivity: A meta-analysis
25. Hyperactivity and diet treatment: A meta-analysis of the Feingold hypothesis
26. Drug treatment of hyperactivity in children
27. Medication and hyperactivity: A meta-analysis
28. Childhood hyperactivity and psychostimulants: A review of extended treatment studies
29. Pharmacotherapy of adult attention deficit/hyperactivity disorder: A review
30. Carbamazepine use in children and adolescents with features of attention-deficit hyperactivity disorder: A meta-analysis
31. Pharmacotherapy of attention-deficit hyperactivity disorder across the life
32. Behavioral and cognitive effects of methylxanthines. A meta-analysis of theophylline and caffeine
33. Pemoline-associated hepatic failure: A critical analysis of the literature
34. The effects of school-based interventions for attention deficit hyperactivity disorder: A meta-analysis
35. Attention deficit disorder and the efficacy of stimulant medication: A meta-analysis
36. Attention-deficit hyperactivity disorder in children and youth: A quantitative systematic review of the efficacy of different management strategies
37. The treatment of attention-deficit hyperactivity disorder: An annotated bibliography and critical appraisal of published systematic reviews and metaanalyses
38. A change of mind: The Conners Abbreviated Rating Scales reconsidered
39. NIMH Collaborative Multisite Multimodal Treatment Study of Children with ADHD: I. Background and rationale
40. Prevalence of ADHD and comorbid disorders among elementary school children screened for disruptive behavior
41. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
42. Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
43. Does blinding of readers affect the results of meta-analyses? University of Pennsylvania blinding study group
44. Variance imputation for overviews of clinical trials with continuous response
45. An assessment of methods to combine published survival curves
46. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: A systemic, placebo-controlled evaluation
47. Meta-analysis of multitreatment studies
48. Tutorial in biostatistics. Meta-analysis: Formulating, combining, and reporting
49. Publication bias: A problem in interpreting medical data
50. Bias in meta-analysis detected by a simple, graphical test
51. A nonparametric "trim and fill" method of accounting for publication bias in meta-analysis
52. Improving the quality of reports of meta-analyses of randomized controlled trials: The QUOROM statement
53. Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate
54. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder?
55. Assessment of stimulant response in ADHD children using a refined multimethod clinical protocol
56. Response to stimulant medication across six measures of school-related performance in children with ADHD and disruptive behavior
57. Increased methylphenidate usage for attention deficit disorder in the 1990s
58. A 14-month randomized clinical trial of treatment strategies for Attention-Deficit/Hyperactivity Disorder
59. Systematic reviews neglect safety issues
60. Reporting of safety data from randomised trials
61. Completeness of safety reporting in randomized trials. An evaluation of 7 medical areas
62. Numbers needed to treat derived from meta-analyses - Sometimes informative, usually misleading
63. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders
64. Gender differences in ADHD: A meta-analysis and critical review
65. Empirical evidence of bias in infertility research: Overestimation of treatment effect in crossover trials using pregnancy as the outcome measure
66. Psychotropic drug use in very young children
67. The use of psychotropic medications in preschoolers: Some recent developments
68. Diagnosis of attention deficit disorder and use of psychotropic medication in very young children
69. Prescribing stimulants for disruptive behaviour disorders: Sometimes against the best interest of the child